Shawn Leung – CEO, SinoMab Bioscience, Hong Kong
Shawn, as I understand, SinoMab today is a clinical stage biopharma company focusing on the development of therapeutic monoclonal antibodies (mAbs) – hence the name. Can you tell us a…
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Disease and Respiratory. We are also selectively active in the areas of autoimmunity, neuroscience and infection. Its presence in Hong Kong – in the name of AstraZeneca Hong Kong – can be traced back to 1999 when AstraZeneca was formed following a merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Both companies were established in Hong Kong in the 1970s.
AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since our establishment, we have been focusing on identifying and bringing in the latest medical solutions as well as seeking ongoing business development. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
Contact
Address: Unit 1-3, 11/F, 18 King Wah Road, North Point
Tel: +(852) 2420 7388
Website: https://www.astrazeneca.com/country-sites/hong-kong.html
Shawn, as I understand, SinoMab today is a clinical stage biopharma company focusing on the development of therapeutic monoclonal antibodies (mAbs) – hence the name. Can you tell us a…
Andy Barnett, general manager (Hong Kong and Macau) for Roche, discusses the highlights of his past two years managing a local affiliate instead of heading a global business line, the…
Lawrence Wong, general manager of Ferring Pharmaceuticals in Hong Kong, discusses the important role of the Hong Kong affiliate in support of regional operations, the value of the Hong Kong…
William Yim and Kelvin Chiu of Sanwa Biotech discuss their innovative company’s impressive growth and the environment for biotech start-up companies in Hong Kong. Despite only having been founded five…
The Hon. Fanny Law Fan Chiu-fun, chairperson, and Prof. Daniel Lee, head of the Biomedical Technology Cluster, at Hong Kong Science and Technology Parks Corporation (HKSTP) discuss Hong Kong’s potential…
Christian Hogg, executive director and CEO of Chi-Med, discusses the company’s rapid development in tandem with the growth of the Chinese pharmaceutical market, brining genuine global pharmaceutical innovation to China,…
Jun Wang, founder and CEO of GeneHarbor Biotechnologies, introduces his company’s innovative technology platform and the specificities of the start-up ecosystem in Hong Kong. Dr. Wang, can you firstly tell…
Albert Yu, Chairman of the Hong Kong Biotechnology Organization, shares his insights on Hong Kong’s potential to become an innovation hub for the region while positioning Hong Kong as the…
See our Cookie Privacy Policy Here
